Evidence map›Paper›PMID 31667795›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2020

Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients.

Faten Farouk, Dina Wahba, Sherif Mogawer, Shaimaa Elkholy, Ahmed Elmeligui, Reham Abdelghani, Salwa Ibahim

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Faten FaroukPharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th October City, Egypt. f.farouk04@gmail.com.ORCID http://orcid.org/0000-0001-6232-5714
Dina WahbaNational Organization of Drug Quality Control and Research, Giza, Egypt.
Sherif MogawerInternal Medicine Department, Hepato-gastroenterology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Shaimaa ElkholyInternal Medicine Department, Hepato-gastroenterology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Ahmed ElmeliguiInternal Medicine Department, Hepato-gastroenterology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Reham AbdelghaniInternal Medicine Department, Nephrology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Salwa IbahimInternal Medicine Department, Nephrology Unit, Faculty of Medicine, Cairo University, Giza, Egypt.
Cairo University · EGAhram Canadian University · EGNational Organization for Drug Control and Research · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe effectiveness of direct-acting antivirals (DAAs) is not well established in end-stage renal disease (ESRD) patients. Assessment of the plasma concentrations may support understanding of their therapeutic outcomes in this population. The aim of this study is to develop a direct, yet matrix-effect tolerant, analytical method for determining DAAs in the plasma of ESRD patients while maintaining a moderate cost per sample and with an improved analyte extraction recovery.

methodsIn this study, a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was developed for the analysis of ombitasvir (OMB), paritaprevir (PRT) and ritonavir (RIT) in plasma. Sample preparation was performed using the liquid-liquid extraction (LLE) method. Isocratic separation was performed using a mixture of methanol and 10 mM ammonium acetate (79:21, v/v) followed by MS/MS detection. The method was validated and applied to determine DAAs in the plasma of ESRD patients (n = 7).

resultsThe developed method was linear (r

conclusionsAn efficient analytical method for the determination of DAAs is presented. The method overcomes the potential analytical response fluctuation in ESRD. The developed method show improved extraction recoveries and is suitable for routine application in developing economies where hepatitis C virus is most prevalent.

Indexed as

AdultAnilidesAntiviral AgentsCarbamatesChromatography, LiquidCyclopropanesDrug StabilityFemaleHumansKidney Failure, ChronicLactams, MacrocyclicMacrocyclic CompoundsMaleMass SpectrometryMiddle AgedPlasmaAnilidesAntiviral AgentsCarbamatesCyclopropanesLactams, MacrocyclicMacrocyclic CompoundsombitasvirparitaprevirProlineRitonavirSulfonamidesValine

Identifiers

PMID31667795
OpenAlexW2982348309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.